KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short term Debt (2016 - 2025)

Teva Pharmaceutical Industries' Short term Debt history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt rose 2.19% year-over-year to $1.8 billion, compared with a TTM value of $1.8 billion through Dec 2025, up 2.19%, and an annual FY2025 reading of $1.8 billion, up 2.19% over the prior year.
  • Short term Debt for Q4 2025 was $1.8 billion at Teva Pharmaceutical Industries, up from $24.0 million in the prior quarter.
  • The five-year high for Short term Debt was $3.5 billion in Q2 2021, with the low at $24.0 million in Q3 2025.
  • Average Short term Debt over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
  • Year-over-year, Short term Debt surged 199.12% in 2024 and then plummeted 99.07% in 2025.
  • Tracing TEVA's Short term Debt over 5 years: stood at $1.4 billion in 2021, then surged by 47.9% to $2.1 billion in 2022, then dropped by 20.72% to $1.7 billion in 2023, then rose by 6.52% to $1.8 billion in 2024, then grew by 2.19% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Short term Debt are $1.8 billion (Q4 2025), $24.0 million (Q3 2025), and $464.0 million (Q2 2025).